Unlike previous studies contrasting DTC risk in null vs. non-null genotypes, CNVs of GSTM1 and GSTT1 were also examined in our study to investigate a potential dose-effect relationship between enzymatic activity and cancer risk. This evidence concerns the gene GSTM1 and cancer.